Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
06:23am, Wednesday, 21'st Jan 2026
Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPEN
Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside
01:36pm, Tuesday, 20'th Jan 2026
On Friday, Genmab A/S (NASDAQ: GMAB) released topline results from the Phase 3 EPCORE DLBCL-1 trial of epcoritamab for diffuse large B-cell lymphoma (DLBCL).
Genmab's blood cancer drug fails main goal in late-stage study
01:35pm, Friday, 16'th Jan 2026
Danish drugmaker Genmab said on Friday that its experimental drug for a type of blood cancer failed to meet the main goal in a late-stage study.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody admi
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Gen
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:05am, Wednesday, 14'th Jan 2026
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Genmab: AI Partnership And Clinical Data Fuel Growth
05:06am, Saturday, 10'th Jan 2026
Genmab is transitioning from a royalty-driven licensor to an innovation powerhouse with a robust, proprietary pipeline. GMAB delivered 21% revenue growth and 52% operating profit growth, supported by
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
09:00am, Wednesday, 07'th Jan 2026
Media Release COPENHAGEN, Denmark; January 07, 2026 Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:58am, Monday, 05'th Jan 2026
Media Release COPENHAGEN, Denmark; January 5, 2026 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44 th Annual J.P. Morgan
Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why
03:38am, Friday, 02'nd Jan 2026
Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) dropped 3.5% on Wednesday. The stock traded as low as $30.38 and last traded at $30.3870. Approximately 482,335 shares traded hands during mid
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:32am, Tuesday, 30'th Dec 2025
Shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the compan
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
12:32pm, Monday, 29'th Dec 2025
Genmab A/S (NASDAQ: GMAB) on Monday said it will discontinue further clinical development of acasunlimab.
Genmab scraps development of experimental cancer therapy
09:03am, Monday, 29'th Dec 2025
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.
Genmab Portfolio Prioritization Update
08:12am, Monday, 29'th Dec 2025
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strateg
Genmab Portfolio Prioritization Update
08:10am, Monday, 29'th Dec 2025
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher ‑ impact opportunities across Genmab's late ‑
